=== PAGE 3 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Bharathi Devarakonda
Eton Pharmaceuticals, Inc.
NDA 213876/MA 13

Page 3

The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential
violations. It is your responsibility to ensure compliance with each applicable requirement of the
FD&C Act and FDA implementing regulations.

Please direct your response to the undersigned at the **Food and Drug Administration, Center for
Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale
Road, Beltsville, Maryland 20705-1266**. A courtesy copy can be sent by facsimile to (301) 847-
8444. To ensure timely delivery of your submissions, please use the full address above and include a
prominent directional notation (e.g., a sticker) to indicate that the submission is intended for OPDP.
Please refer to MA 13 in addition to the NDA number in all future correspondence relating to this
particular matter. All correspondence should include a subject line that clearly identifies the
submission as a Response to Untitled Letter.

Sincerely,

{See appended electronic signature page}

Charuni Shah, PharmD
Regulatory Review Officer
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

{See appended electronic signature page}

Melinda Wilson, PharmD, MPH, BCPS, RAC
Team Leader
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

Reference ID: 4837593
